Compare Impinj Inc (PI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Viatris Inc — how do they compare? Impinj Inc trades at $186 (market cap $5.60B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.6× Impinj Inc's market cap, and Viatris Inc pays a 2.75% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Viatris Inc for 57 Days on average.
| PI | VTRS | |
|---|---|---|
Market Cap | $5.60B | $20.03B |
Volume | 9,929 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $241.91 | $18.27 |
52-Week Low | $91.34 | $9.74 |
Typical Hold Time | 22 Days | 57 Days |
Enterprise Value | $5.73B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $191.04, up 3.81% with strong technical momentum and bullish moving average signals. The company shows revenue growth with Q2 2026 earnings beating estimates, though profitability remains challenged with negative net margins. Analyst consensus is strongly bullish with 16 buy ratings and a $178.83 price target, while recent news highlights the company's positioning in RFID technology and upcoming Q3 earnings.
The stock presents growth potential from expanding RFID adoption but faces risks from persistent unprofitability and high valuation multiples. Current technical strength and institutional interest support near-term upside, though investors should monitor Q3 earnings results and margin improvement for sustained momentum.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
